TrialThe Lancet. Oncology2017

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Derek Alderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.